Drugs / ERW316
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07570966 | Jun 2026 → Aug 2031 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERW316 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07570966 ↗ |
| Route | Oral | “Oral administration” NCT07570966 ↗ |